Your browser doesn't support javascript.
loading
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
Saura, Cristina; Roda, Desamparados; Roselló, Susana; Oliveira, Mafalda; Macarulla, Teresa; Pérez-Fidalgo, José Alejandro; Morales-Barrera, Rafael; Sanchis-García, Juan Manuel; Musib, Luna; Budha, Nageshwar; Zhu, Jin; Nannini, Michelle; Chan, Wai Y; Sanabria Bohórquez, Sandra M; Meng, Raymond D; Lin, Kui; Yan, Yibing; Patel, Premal; Baselga, José; Tabernero, Josep; Cervantes, Andrés.
Afiliação
  • Saura C; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Roda D; Hematology and Medical Oncology Department, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Roselló S; Hematology and Medical Oncology Department, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Oliveira M; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Macarulla T; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Pérez-Fidalgo JA; Hematology and Medical Oncology Department, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Morales-Barrera R; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Sanchis-García JM; Radiology Department, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Musib L; Genentech, Inc., South San Francisco, California.
  • Budha N; Genentech, Inc., South San Francisco, California.
  • Zhu J; Genentech, Inc., South San Francisco, California.
  • Nannini M; Genentech, Inc., South San Francisco, California.
  • Chan WY; Genentech, Inc., South San Francisco, California.
  • Sanabria Bohórquez SM; Genentech, Inc., South San Francisco, California.
  • Meng RD; Genentech, Inc., South San Francisco, California.
  • Lin K; Genentech, Inc., South San Francisco, California.
  • Yan Y; Genentech, Inc., South San Francisco, California.
  • Patel P; Genentech, Inc., South San Francisco, California.
  • Baselga J; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Tabernero J; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain. jtabernero@vhio.net.
  • Cervantes A; Hematology and Medical Oncology Department, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
Cancer Discov ; 7(1): 102-113, 2017 01.
Article em En | MEDLINE | ID: mdl-27872130
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Pirimidinas / Inibidores de Proteínas Quinases / Neoplasias Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Discov Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Espanha País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Pirimidinas / Inibidores de Proteínas Quinases / Neoplasias Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Discov Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Espanha País de publicação: Estados Unidos